NCT02155088View on ClinicalTrials.gov

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 30, 2014

Primary Completion Date

December 1, 2016

Study Completion Date

January 31, 2020

Conditions
Pancreatic Cancer
Interventions
DRUG

BYL719

Dose escalation beginning at 250 mg/day

DRUG

Gemcitabine

Dose escalation beginning at 800 mg/m\^2

DRUG

(nab)-paclitaxel

125 mg/m\^2 dose

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT02155088 - BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter